Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja's novel approach is powered by integrated cellular immunotherapy technologies comprising the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/15/21 | $210,000,000 | Series B |
CaaS Capital Management Casdin Capital Cormorant Asset Management  DCVC MPM Capital Presight Captial Qiming Venture Partners RTW Investments SoftBank Vision Fund 2 Temasek The Emerson Collective | undisclosed |
